Elicio Therapeutics to be Acquired by Angion Biomedica
Ticker: ELTX · Form: 8-K · Filed: May 24, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
Elicio Therapeutics is being bought by Angion Biomedica, deal expected to close Q3 2024.
AI Summary
Elicio Therapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Angion Biomedica Corp. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition will combine Elicio's AMPLIFY platform with Angion's expertise in regenerative medicine.
Why It Matters
This acquisition signifies a consolidation in the biotechnology sector, potentially impacting the development and availability of Elicio's novel immunotherapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the integration of the two companies may present challenges.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Acquiring company
- May 23, 2024 (date) — Date of definitive agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Elicio Therapeutics, Inc. has entered into a definitive agreement to be acquired by Angion Biomedica Corp.
Who is acquiring Elicio Therapeutics, Inc.?
Angion Biomedica Corp. is acquiring Elicio Therapeutics, Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is Elicio Therapeutics' key platform mentioned in the filing?
Elicio Therapeutics' AMPLIFY platform is mentioned as being combined with Angion's expertise.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-23 17:41:48
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
Filing Documents
- angn-20240523.htm (8-K) — 22KB
- a2024-05x23xxeltxxxph1am.htm (EX-99.1) — 14KB
- a2024-05x23xxeltxxxph1am001.jpg (GRAPHIC) — 289KB
- a2024-05x23xxeltxxxph1am002.jpg (GRAPHIC) — 254KB
- a2024-05x23xxeltxxxph1am003.jpg (GRAPHIC) — 319KB
- a2024-05x23xxeltxxxph1am004.jpg (GRAPHIC) — 129KB
- 0001601485-24-000037.txt ( ) — 1533KB
- angn-20240523.xsd (EX-101.SCH) — 2KB
- angn-20240523_lab.xml (EX-101.LAB) — 22KB
- angn-20240523_pre.xml (EX-101.PRE) — 13KB
- angn-20240523_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On May 23, 2024, Elicio Therapeutics, Inc. issued a press release announcing its presentation of preliminary data from the ongoing AMPLIFY-7P Phase 1 study of its investigational therapeutic cancer vaccine candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors at the 2024 American Society of Clinical Oncology Annual Meeting being held May 31-June 4, 2024 in Chicago, Illinois. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated May 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: May 23, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)